The European Commission has licensed Avastin in combination with standard chemotherapy for the treatment of women with advanced cervical cancer. Until now, the treatment has been available ahead of licence to eligible patients in England via individual requests to the Cancer Drugs Fund (CDF).

Excerpt from:
First new treatment authorised in a decade for advanced cervical cancer patients in the UK

Scroll to Top